Why the study?
The analytical performance of the new Sysmex HISCL hs-cTnT assay, its comparison to the Roche assay, its 99th-percentile URLs, and the effects of age and eGFR required evaluation.
Does the new Sysmex HISCL high-sensitivity cardiac troponin T assay demonstrate comparable analytical performance to the Roche Elecsys assay and fulfill international criteria for a high-sensitivity assay in healthy and chronic kidney disease cohorts?
Does the new Sysmex HISCL high-sensitivity cardiac troponin T assay demonstrate comparable analytical performance to the Roche Elecsys assay and fulfill international criteria for a high-sensitivity assay in healthy and chronic kidney disease cohorts?
Answers are grounded in this paper and cite their sources.
The new Sysmex HISCL hs-cTnT assay fulfills international criteria for a high-sensitivity troponin assay and demonstrates strong analytical agreement (r = 0.95) with the established Roche Elecsys hs-cTnT assay.
Background: We evaluated the Sysmex Highly Integrated Single-Cartridge Luminescence Immunoassay System (HISCL) hs-cTnT assay, and compared its performance to the Roche assay, with derivation of 99th-percentile upper reference limits (99% URLs) for healthy subjects. We assessed the effect of increasing age/decreasing eGFR on the HISCL hs-cTnT. Methods: We verified assay limits of blank/detection, precision and the functional sensitivity. Samples were analyzed on both the Sysmex HISCL and Roche Elecsys analyzers for method comparison. Results: The HISCL assay limit of blank/detection was 1.3/1.9 ng/L, and concentrations corresponding to 20/10% CVs were 1.8/3.3 ng/L. Assay precision of kit controls at 3253 ng/L was 2.2% and at 106 ng/L was 2.5%. Linear regression analysis (n = 2151) showed good agreement (r = 0.95) with the Roche hs-cTnT. Bland–Altman (Roche/HISCL) analysis for samples with hs-cTnT ≤ 52 ng/L showed a mean absolute difference of 3.5 ng/L; for hs-cTnT > 52 ng/L, the mean difference was 2.8%. In a cardio-renal healthy population (n = 1004), the 99% URLs were 14.4/17.0/13.9 ng/L for overall/male/female, respectively; assay CV% was below 10% at these levels. More than 50% of the hs-cTnT in the healthy male and female subjects were measurable above the limit of detection. Hs-cTnT increased with increasing age and decreasing eGFR. Conclusions: In conclusion, the Sysmex HISCL hs-cTnT fulfils the criteria for a high-sensitivity assay, with specific 99th URLs for males and females. Expectedly, the baseline Sysmex hs-cTnT increases with age and decreasing eGFR.
No takes yet. Share an insight, caveat, or question.
Lau et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: